Detalhe da pesquisa
1.
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Lancet
; 401(10370): 25-37, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493791
2.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Lancet
; 401(10370): 38-48, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495881
3.
Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies.
Rheumatology (Oxford)
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754125
4.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ann Rheum Dis
; 82(11): 1404-1414, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696588
5.
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.
Rheumatology (Oxford)
; 62(2): 617-628, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35789257
6.
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Lancet
; 395(10222): 427-440, 2020 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32035552
7.
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis.
RMD Open
; 10(1)2024 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38296802
8.
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
RMD Open
; 10(1)2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388171
9.
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Arthritis Rheumatol
; 74(12): 1959-1970, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35829656
10.
Small ubiquitin-like modifier 1 [corrected] mediates the resistance of prosthesis-loosening fibroblast-like synoviocytes against Fas-induced apoptosis.
Arthritis Rheum
; 60(7): 2065-70, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19565496
11.
Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.
Proc Natl Acad Sci U S A
; 104(12): 5073-8, 2007 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-17360386
12.
NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins.
J Biol Chem
; 278(28): 25637-43, 2003 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-12730221